304am永利集团|·主頁(歡迎您)

Be the most trusted biotech company

2019-02-12

New progress! Henlius HLX22 Received Clinical Approval from NMPA
2019-01-29

Henlius Completed Phase 1/2 Study of Its Rituximab Injection for Rheumatoid Arthritis
2019-01-24

Henlius Adalimumab Received Acceptance of New Drug Application
2018-11-29

Henlius Completed Data Analysis of the Phase 1 Study for Its HLX03
2018-11-26

Henlius HLX22 Received IND Application Acceptance Notification from NMPA
2018-11-16

Henlius Successfully Held Its Second Scientific Advisory Board (SAB) Meeting in California
2018-11-01

Cooperation Upgrades! Henlius Has been Granted to Develop and Commercialize AC101 in the World
2018-10-26

New Progress! Henlius Received Clinical Approval for Its Anti-VEGFR2 Monoclonal Antibody, HLX12
2018-10-18

Henlius Nominated for the Global Generics & Biosimilars Awards 2018 in Two Categories